Good day, ladies and gentlemen, and welcome to the Year End 2013 PharmAthene Incorporated Earnings Conference Call. My name is Crystal, and I will be your operator for today. At this time all participants are in listen-only mode. Later, we will conduct a question-and-answer session. (Operator Instructions) As a reminder, this conference is being recorded for replay purposes. I would now like to turn the conference over to your host for today, Ms. Stacey Jurchison. Please proceed.

Thank you, and good afternoon, everyone. Joining me on the call today are Eric Richman, President and Chief Executive Officer; and Linda Chang, Senior Vice President and Chief Financial Officer. Before we begin, I would like to point out that during today's call, we will be making projections and other forward-looking statements, which are based on our current beliefs and expectations. Please be aware that these statements are subject to certain risks and uncertainties. We advise you to consult PharmAthene's filings with the SEC for additional information. I will now turn the call over to Eric to begin.

Good afternoon and thank you for joining us today for our year-end business review. Linda will take you through our financial results for 2013 in just a moment. But first I will provide a high level summary of recent activities and our expectations for 2014. Let’s begin with a brief review of our SparVax program. We are continuing to execute under our current contract and have made important progress in many areas including GMP manufacturing, immunobiology and the non-clinical animal studies, all of which lead to continue clinical studies. We recently completed a non-clinical efficacy study of SparVax in the New Zealand White Rabbit Model. This is a widely accepted model which has been used historically to measure the efficacy of anthrax vaccines. The study was designed to evaluate the efficacy of SparVax at three different doses compared to the currently licensed anthrax vaccine BioThrax and the accepted model for inhalation anthrax infection. The in-light portion of the study has been completed and I am pleased to report that SparVax performed very well. The data showed 100% survival for both products at the estimated human equivalent dose and demonstrated non-inferiority of our product and in aerosol challenge study where rabbits were exposed to approximately 22 million scores of anthrax. Under the FDA’s animal rule, human efficacy can be calculated by comparing immunogenicity data in humans to immunogenicity and efficacy data in accepted animal models. So we are particularly encouraged by these data. We are also encouraged by the fact that the product used in this study was nearly two years old and showed a strong protected effect. Having demonstrated impressive non-clinical data, our main priority now is to correlate the animal data with the immunogenicity in humans and determine an estimate of efficacy. We were preparing to begin a Phase…

Thank you, Eric. Hopefully by now you have seen our 2013 year-end earnings press release which we issued aftermarket today, I will briefly review the key financials and refer you to our latest SEC filing for additional information. We reported 17.9 million in contract revenue for 2013, compared to 25.2 million for the same period in 2012. Revenue was lower in 2013 due to the narrower scope of development activity in our SparVax program as a result of the FDA clinical hold, and also the partial federal government shutdown in October. Correspondingly, our R&D expenses for the year were also lower at 15.3 million compared to 19.5 million in 2012. Our G&A expenses in 2013 were higher at 13.3 million compared to 11.6 million in 2012. The increase in G&A expenses include a one-time charge of 3.3 million relating to the terminated merger with Theraclone Sciences. In terms of our cash position, we ended the year with approximately 10.5 million in cash and equivalents while our combined cash and receivable balance totaled approximately 14.1 million. Finally, our net loss for the year was 11.6 million, or $0.23 per share, compared to a net loss of 4.9 million, or $0.10 per share in 2012 due to the reasons I have just described. In 2014, we will continue to operate with the same degree of efficiency demonstrated in recent years and carefully manage our cash usage while we pursue additional U.S. government funding for our programs and await the outcome of the SIGA litigation. With that, I will turn the call back to Eric to wrap up.

Thank you, Linda. We look forward to keeping you updated on our progress in 2014. We have a clear path forward to address the SparVax clinical hold and we’re making progress with regard to these efforts. Our goal is to resume clinical development of SparVax this year and we’re firmly committed to working with the FDA and BARDA to achieve this. Finally, we anticipate a ruling from the Delaware Court of Chancery soon and expect that the decision will be significant event for PharmAthene. We look forward to sharing this information with investors and we’ll keep you apprise of any developments. That concludes my prepared remarks of today. Operator, could you please open the call for questions.

and:

(Operator Instructions) With no questions in the queue, I will now turn the call back to Eric for closing remarks.

Thank you again for joining us today and for your continued interest in PharmAthene. Have a good evening.